ClinicalTrials.gg
RecruitingNCT07656142Updated Oct 23, 2026

A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease

An interventional study of Mobile Application-Based Personalized Temperature Health Risk Early Warning Intervention in Chronic Obstructive Pulmonary Disease, sponsored by Tiantian Li. Recruiting at 4 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Tiantian Li · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 23, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 111 open to participants now, 128 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
120th of 289
240 · median 160
Started
2026
with 36 others
No phase
121 of 407
32 open now
Primary completion
2027-08
later than 75 of 127 live
Registered
388th of 407
by date

Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 120th largest by planned enrollment of the 289 interventional ones that give a count, is one of 37 that started in 2026, is one of 121 with no phase, reaches primary completion later than 75 of the 127 other live ones, and was the 388th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

111 of the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

105 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

This study will test whether a personalized mobile application that provides temperature-related health risk warnings and protective recommendations can reduce acute exacerbations in people with chronic obstructive pulmonary disease (COPD). Researchers will compare participants who receive the mobile application in addition to usual care with those who receive usual care alone. The main question is whether the mobile application reduces the number of COPD acute exacerbation events over 12 months. The study will also evaluate secondary outcomes including quality of life, functional capacity, symptoms, psychological status, physiological and biochemical indicators, environmental temperature risk perception, and participants' use of the mobile application.

Read the detailed description

This study is a proof-of-concept study using a cluster randomized controlled design, with hospitals serving as the unit of randomization. Four eligible hospitals in Beijing will be selected as study sites, and each hospital together with all eligible participants enrolled at that site will be treated as one cluster. Clusters will be randomly assigned in a 1:1 ratio to the intervention group or the control group. In addition to usual COPD care, participants in the intervention group will receive temperature-related health risk warning messages and corresponding protective recommendations generated from real-time meteorological data and individual characteristics through the personalized mobile application. Participants in the control group will receive usual COPD care only without access to the mobile application. The study includes a baseline assessment and a 12-month follow-up period. Study visits will occur at baseline and at 3, 6, 9, and 12 months after enrollment. Baseline assessments will include demographic information, air-conditioner use, smoking and alcohol consumption, health status, acute exacerbation events, quality of life, functional capacity, symptoms, psychological status, environmental temperature perception, and physiological and biochemical indicators. Follow-up assessments will collect acute exacerbation events, quality of life, functional capacity, symptoms, psychological status, physiological and biochemical indicators, environmental temperature perception and participants' use of the mobile application. Due to the cluster design and the nature of the mobile application intervention, study participants and research staff who collect visit data will be unmasked. However, data analysts and members of the endpoint adjudication committee will remain masked to the randomization assignments.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • Temperature-related Health Risk
  • Mobile Application Intervention
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Hospital inclusion criteria:

  1. Tertiary hospitals;
  2. Hospitals with respiratory wards that admit patients with ;
  3. Hospitals with a well-established electronic health record system and follow-up capability;
  4. Hospitals able to assign a study coordinator.

Patient inclusion criteria:

  1. Age >=40 years and \<=80 years, with no restriction on sex;
  2. Patients with stable chronic obstructive pulmonary disease;
  3. At least 1 severe acute exacerbation requiring hospitalization, or at least 2 moderate acute exacerbations requiring outpatient or emergency care, within the previous year;
  4. Local permanent residents with a duration of residence >=6 months;
  5. Patients who voluntarily agree to participate, are expected to have good adherence, are able to sign ;
  6. Patients who own a smartphone or other smart device.

Hospital exclusion criteria:

  1. Primary hospitals or private hospitals;
  2. Hospitals unable to cooperate with the study protocol.

Patient exclusion criteria:

  1. Patients with asthma;
  2. Women who are known to be pregnant or breastfeeding, or who have a positive pregnancy test before cluster randomization;
  3. Patients with other diseases that may affect participation in the trial, such as hypertension or severe aphasia;
  4. Patients currently receiving psychiatric or psychological treatment that may contaminate study results;
  5. Expected survival time \<1 year, such as in those with malignant tumors or severe cardiopulmonary disease;
  6. Participation in other interventional clinical studies that may affect outcome assessment;
  7. Any other circumstances in which the investigator considers the patient unsuitable for participation in this study or at significant risk, such as cognitive impairment preventing understanding of and/or compliance with study procedures and/or follow-up.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Personalized Temperature Risk Intervention + Usual COPD Care

    Other: Mobile Application-Based Personalized Temperature Health Risk Early Warning Intervention

  • No intervention
    Usual COPD Care

Interventions

  • OtherMobile Application-Based Personalized Temperature Health Risk Early Warning Intervention

    This study implements a digital early warning intervention targeting personalized temperature-related health risks. The mobile application integrates real-time meteorological data and individual characteristics to generate risk levels and deliver tailored health alerts and guidance aimed at supporting risk management and reducing exposure-related health risks.

06

What researchers measure

Primary outcomes

  1. Number of COPD Acute Exacerbations

    Total number of acute exacerbations of COPD managed at home, via outpatient visits, emergency department visits, or hospitalizations.

    Time frame: 12 months after baseline

Secondary outcomes

  1. Number of Home-managed COPD Acute Exacerbations

    Number of home-managed COPD acute exacerbations

    Time frame: 6 and 12 months after baseline

  2. Number of Outpatient-managed COPD Acute Exacerbations

    Number of outpatient-managed COPD acute exacerbations

    Time frame: 6 and 12 months after baseline

  3. Number of Emergency Department-managed COPD Acute Exacerbations

    Number of emergency department-managed COPD acute exacerbations

    Time frame: 6 and 12 months after baseline

  4. Number of Hospitalized COPD Acute Exacerbations

    Number of hospitalized COPD acute exacerbations

    Time frame: 6 and 12 months after baseline

  5. Changes in St. George's Respiratory Questionnaire for COPD Patients Score

    The St. George's Respiratory Questionnaire for COPD patients (SGRQ-C) score ranges from 0 to 100. Higher scores indicate a worse outcome (poorer health-related quality of life).

    Time frame: 3, 6, 9, and 12 months after baseline

  6. Changes in EuroQol 5-Dimension 5-Level Score

    The EuroQol 5-Dimension 5-Level (EQ-5D-5L) score consists of two parts: a questionnaire and a visual analogue scale (VAS). The questionnaire includes five dimensions, where higher scores indicate worse health status. The VAS asks respondents to rate their overall health status on a 0-100 scale. Higher scores on the VAS mean a better outcome (better self-rated health status).

    Time frame: 3, 6, 9, and 12 months after baseline

  7. Change from Baseline in Forced Expiratory Volume in 1 Second

    Forced Expiratory Volume in 1 Second (FEV1) will be measured in liters using spirometry.

    Time frame: 6 and 12 months after baseline

  8. Change from Baseline in Forced Vital Capacity

    Forced Vital Capacity (FVC) will be measured in liters using spirometry.

    Time frame: 6 and 12 months after baseline

  9. Change from Baseline in Percent Predicted FEV1

    Percent Predicted Forced Expiratory Volume in 1 Second (FEV1%pred) will be calculated from spirometry and expressed as a percentage of the predicted value.

    Time frame: 6 and 12 months after baseline

  10. Changes in Blood Pressure

    Measured using a sphygmomanometer.

    Time frame: 3, 6, 9, and 12 months after baseline

  11. Number of Participants With Abnormal Electrocardiogram Readings

    Abnormal electrocardiogram (ECG) readings will be identified from standard clinical ECG reports by qualified physicians. The total number of participants with these abnormal readings will be counted. A lower number of participants with abnormal ECG readings means a better outcome (better cardiac safety profile).

    Time frame: 3, 6, 9, and 12 months after baseline

  12. Changes in Blood Oxygen Saturation

    Measured using a pulse oximeter.

    Time frame: 3, 6, 9, and 12 months after baseline

  13. Changes in Modified Medical Research Council Score

    The modified Medical Research Council (mMRC) score ranges from 0 to 4. Higher scores mean a worse outcome (more severe dyspnea).

    Time frame: 3, 6, 9, and 12 months after baseline

  14. Changes in the COPD Assessment Test Questionnaire Score

    The COPD Assessment Test (CAT) total score ranges from 0 to 40. Higher scores mean a worse outcome (a greater impact of COPD on patient's health status).

    Time frame: 3, 6, 9, and 12 months after baseline

  15. Changes in 7-item Generalized Anxiety Disorder Questionnaire Score

    The 7-item Generalized Anxiety Disorder (GAD-7) questionnaire score ranges from 0 to 21. Higher scores mean a worse outcome (more severe anxiety symptoms).

    Time frame: 3, 6, 9, and 12 months after baseline

  16. Changes in 9-item Patient Health Questionnaire Score

    The 9-item Patient Health Questionnaire (PHQ-9) score ranges from 0 to 27. Higher scores mean a worse outcome (more severe depressive symptoms).

    Time frame: 3, 6, 9, and 12 months after baseline

  17. Changes in Environmental Temperature Risk Perception Score

    Used to assess the participant's awareness and perception of health risks related to environmental temperature on the basis of the Temperature Risk Perception Questionnaire.

    Time frame: 3, 6, 9, and 12 months after baseline

  18. Number of Participants With Abnormal Complete Blood Count Results

    Abnormal complete blood count (CBC) readings will be identified from standard clinical CBC reports by qualified physicians. The total number of participants with these abnormal readings will be counted. A lower number of participants with abnormal CBC readings means a better outcome (better clinical safety profile).

    Time frame: 12 months after baseline

  19. Frequency of Personalized Mobile Application Use

    Assessed using backend data statistics from the personalized Mobile Application.

    Time frame: 3, 6, 9, and 12 months after baseline

  20. Satisfaction with Personalized Mobile Application

    Participant satisfaction with the personalized mobile application will be evaluated using the 10-item System Usability Scale (SUS). The SUS total score ranges from 0 to 100. Higher scores mean a better outcome (greater perceived usability and higher patient satisfaction with the mobile application).

    Time frame: 3, 6, 9, and 12 months after baseline

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 18, 2026
StartActual
Aug 4, 2026was Jun 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
4 sites added — first site in China
Show 4 added (4 China)
  • Beijing Anzhen Hospital, Capital Medical University · Beijing, China
  • Beijing Huairou Hospital · Beijing, China
  • Civil Aviation General Hospital · Beijing, China
  • Emergency General Hospital · Beijing, China
Oct 23, 2026
Start date
Jun 2026→Aug 4, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    4 sites added — first site in China
    Show 4 added (4 China)
    • Beijing Anzhen Hospital, Capital Medical University · Beijing, China
    • Beijing Huairou Hospital · Beijing, China
    • Civil Aviation General Hospital · Beijing, China
    • Emergency General Hospital · Beijing, China
    Start date Jun 2026→Aug 4, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07656142
Lead sponsor
Tiantian Li
Responsible party
Tiantian Li (professor, Centers for Disease Control and Prevention, China) — Sponsor-investigator
First posted
Jun 18, 2026
Start date
Aug 4, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Can Zhang, Ph.D.
Contact
zhangcan@nieh.chinacdc.cn
+8613655181384

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion